Theravance Biopharma (NASDAQ:TBPH) Given New $15.00 Price Target at TD Cowen

Theravance Biopharma (NASDAQ:TBPH) had its target price hoisted by TD Cowen from $13.00 to $15.00 in a research note published on Monday,Benzinga reports. They currently have a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on TBPH. BTIG Research reiterated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. HC Wainwright boosted their price target on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. B. Riley Financial reaffirmed a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Finally, Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.33.

Theravance Biopharma Trading Up 2.9%

NASDAQ:TBPH opened at $14.75 on Monday. The company has a market cap of $747.38 million, a PE ratio of 7.27 and a beta of 0.17. The company has a 50 day simple moving average of $17.91 and a two-hundred day simple moving average of $16.89. Theravance Biopharma has a 12 month low of $7.90 and a 12 month high of $21.03.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in Theravance Biopharma in the 1st quarter valued at $101,000. Jane Street Group LLC boosted its holdings in shares of Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Theravance Biopharma by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock valued at $9,863,000 after purchasing an additional 3,416 shares during the last quarter. Creative Planning purchased a new position in shares of Theravance Biopharma during the second quarter valued at about $139,000. Finally, American Century Companies Inc. increased its holdings in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 5,794 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.